PIPELINE

 

CHANGING THE FACE OF CANNABIS RESEARCH

The Company is developing therapeutic products for:

 

Sleep

Pain

Parkinson’s Disease

 

Sleep

 

Together with Ci-Therapeutics, CannRx is bringing to market ican.sleep.

 

ican.sleep is the first Cannaceutical (GMP, pharmaceutical grade cannabis product) planned to be available to the tens of millions suffering from sleep disorders, a widespread ailment that affects 30% of the adult population.

 

We have identified a proprietary cannabinoid profile, CRX-102, which demonstrates a profound and consistent effect on sleep disorders. CRX-102 testing used an established, validated and predictive animal model based on a standard dose of diazepam (10 mg), a well-known and commonly used prescription drug for anxiety and sleep disorders, as a positive control. The data demonstrated that the CRX-102 product is able to generate a response rate and predictable onset of sleep similar to those of diazepam. Remarkably, CRX-102 demonstrated a statistically significantly longer duration of sleep, more than twice as long as diazepam. Moreover, there were fewer episodes of nighttime awakening and no apparent “hangover effect” upon waking.

 

To learn more visit www.ci-therapeutics.com

 

Pain

 

Pain is highly prevalent in advanced cancer patients, with two thirds of this population experiencing pain. Pain in cancer patients may be caused from the cancer tumor or side effects from cancer treatments. Severe flare ups of pain are called breakthrough pain as the pain breaks through the regular pain medication. This breakthrough pain has an incidence of about 40-86% as reported in various studies. The World Health Organization (WHO) introduced a pain ladder in 1986 that has been accepted worldwide. Combined with appropriate dosage guidelines, it should be able to provide tools for adequate pain relief in 70%-90% of the patients. Despite the clear WHO recommendations, cancer pain still is a major problem.

 

Parkinson’s Disease

 

It is estimated that 6.3 million people currently have Parkinson’s Disease worldwide. A 2004 Study estimated the number of individuals aged over 50 with Parkinson’s Disease in Western Europe’s five most populous nations (Germany, France, the UK, Italy and Spain) and the world’s 10 most populous nations (China, India, the US, Indonesia, Brazil, Pakistan, Bangladesh, Russia, Nigeria and Japan) was between 4.1 and 4.6 million. It was projected that by 2030 this number will more than double to between 8.7 and 9.3 million. About 70% of people with Parkinson’s have tremor when first diagnosed, with rest tremor and action tremor being equally common.

 

 

CannRx Technology Inc.

One Rockefeller Plaza, 11th Floor

New York, NY 10020

www.cannrx.com

 

CONTACT/SUPPORT

Tel:  646-224-6966

Fax: 646-224-6965

info@cannrx.com

 

 

© 2016 Copyright by CannRx Technology Inc. All Rights Reserved.

FOLLOW US